{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:57:51Z","timestamp":1790258271917,"version":"4.1.0"},"reference-count":34,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2018,5,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> This clinical practice guideline addresses abiraterone or docetaxel with androgen-deprivation therapy (ADT) for metastatic prostate cancer that has not been treated (or has been minimally treated) with testosterone-lowering agents. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> Standard therapy for newly diagnosed metastatic prostate cancer has been ADT alone. Three studies have compared ADT alone with ADT and docetaxel, and two studies have compared ADT alone with ADT and abiraterone. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Three prospective randomized studies (GETUG-AFU 15, STAMPEDE, and CHAARTED) examined overall survival (OS) with adding docetaxel to ADT. STAMPEDE and CHAARTED favored docetaxel (hazard ratio [HR], 0.78; 95% CI, 0.66 to 0.93; n = 2,962 and HR, 0.73; 95% CI, 0.59 to 0.89; n = 790, respectively). GETUG-AFU 15 was negative. LATITUDE and STAMPEDE examined the impact on OS of adding abiraterone (with prednisone or prednisolone) to ADT. LATITUDE and STAMPEDE favored abiraterone (HR, 0.62; 95% CI, 0.51 to 0.76; n = 1,199 and HR, 0.63; 95% CI, 0.52 to 0.76; n = 1,917, respectively). <\/jats:p><\/jats:sec><jats:sec><jats:title>Recommendations<\/jats:title><jats:p> ADT plus docetaxel or abiraterone in newly diagnosed metastatic non-castrate prostate cancer offers a survival benefit as compared with ADT alone. The strongest evidence of benefit with docetaxel is in men with de novo high-volume (CHAARTED criteria) metastatic disease. Similar survival benefits are seen using abiraterone acetate in high-risk patients (LATITUDE criteria) and in the metastatic population in STAMPEDE. ADT plus abiraterone and ADT plus docetaxel have not been compared, and it is not known if some men benefit more from one regimen as opposed to the other. Fitness for chemotherapy, patient comorbidities, toxicity profiles, quality of life, drug availability, and cost should be considered in this decision. Additional information is available at www.asco.org\/genitourinary-cancer-guidelines . <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2018.78.0619","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T19:59:55Z","timestamp":1522699195000},"page":"1521-1539","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":49,"title":["Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline"],"prefix":"10.1200","volume":"36","author":[{"given":"Michael J.","family":"Morris","sequence":"first","affiliation":[{"name":"Michael J. Morris and Dana Rathkopf, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Ethan Basch and Matthew I. Milowsky, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Sebastien J. Hotte, Juravinski Cancer Centre, Hamilton; Andrew Loblaw, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Paul Celano, Greater Baltimore Medical Center, Towson, MD; and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Bryan","family":"Rumble","sequence":"additional","affiliation":[{"name":"Michael J. Morris and Dana Rathkopf, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Ethan Basch and Matthew I. Milowsky, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Sebastien J. Hotte, Juravinski Cancer Centre, Hamilton; Andrew Loblaw, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Paul Celano, Greater Baltimore Medical Center, Towson, MD; and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Basch","sequence":"additional","affiliation":[{"name":"Michael J. Morris and Dana Rathkopf, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Ethan Basch and Matthew I. Milowsky, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Sebastien J. Hotte, Juravinski Cancer Centre, Hamilton; Andrew Loblaw, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Paul Celano, Greater Baltimore Medical Center, Towson, MD; and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien J.","family":"Hotte","sequence":"additional","affiliation":[{"name":"Michael J. Morris and Dana Rathkopf, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Ethan Basch and Matthew I. Milowsky, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Sebastien J. Hotte, Juravinski Cancer Centre, Hamilton; Andrew Loblaw, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Paul Celano, Greater Baltimore Medical Center, Towson, MD; and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Loblaw","sequence":"additional","affiliation":[{"name":"Michael J. Morris and Dana Rathkopf, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Ethan Basch and Matthew I. Milowsky, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Sebastien J. Hotte, Juravinski Cancer Centre, Hamilton; Andrew Loblaw, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Paul Celano, Greater Baltimore Medical Center, Towson, MD; and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Rathkopf","sequence":"additional","affiliation":[{"name":"Michael J. Morris and Dana Rathkopf, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Ethan Basch and Matthew I. Milowsky, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Sebastien J. Hotte, Juravinski Cancer Centre, Hamilton; Andrew Loblaw, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Paul Celano, Greater Baltimore Medical Center, Towson, MD; and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Celano","sequence":"additional","affiliation":[{"name":"Michael J. Morris and Dana Rathkopf, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Ethan Basch and Matthew I. Milowsky, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Sebastien J. Hotte, Juravinski Cancer Centre, Hamilton; Andrew Loblaw, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Paul Celano, Greater Baltimore Medical Center, Towson, MD; and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Bangs","sequence":"additional","affiliation":[{"name":"Michael J. Morris and Dana Rathkopf, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Ethan Basch and Matthew I. Milowsky, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Sebastien J. Hotte, Juravinski Cancer Centre, Hamilton; Andrew Loblaw, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Paul Celano, Greater Baltimore Medical Center, Towson, MD; and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[{"name":"Michael J. Morris and Dana Rathkopf, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Ethan Basch and Matthew I. Milowsky, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Sebastien J. Hotte, Juravinski Cancer Centre, Hamilton; Andrew Loblaw, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Paul Celano, Greater Baltimore Medical Center, Towson, MD; and..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8404"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.11.005"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70560-0"},{"key":"B7","doi-asserted-by":"crossref","unstructured":"Patrick-Miller LJ, Chen Y-H, Carducci MA, et al: Quality of life (QOL) analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PrCa). J Clin Oncol 34, 2016 (suppl; abstr 286)","DOI":"10.1200\/jco.2016.34.2_suppl.286"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw372.04"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01037-5"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/amiajnl-2011-000172"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-4-200708210-00179"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.09.013"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00489-1"},{"key":"B18","unstructured":"Reference deleted."},{"key":"B19","doi-asserted-by":"crossref","unstructured":"Chi KN, Protheroe A, Rodriguez-Antolin A, et al: Benefits of abiraterone acetate plus prednisone (AA+P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Presented at the European Society for Medical Oncology 2017 Congress, Madrid, Spain, September 8-12, 2017","DOI":"10.1093\/annonc\/mdx370"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.07.003"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.38.1.73"},{"key":"B22","first-page":"293","volume":"4","author":"Huggins C","year":"1941","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1941.01210140043004"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0944"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71205-7"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0133"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20955"},{"key":"B33","unstructured":"Lin K, Croswell JM, Koenig H, et al: Prostate-Specific Antigen-Based Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force. Rockville, MD, Agency for Healthcare Research and Quality, 2011"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7270"},{"key":"B35","unstructured":"Centers for Disease Control and Prevention: United States Cancer Statistics: 1999-2012 Incidence and Mortality Web-Based Report. https:\/\/nccd.cdc.gov\/uscs\/"},{"key":"B38","unstructured":"American Cancer Society: Cancer Facts and Figures for African Americans 2016-2018. http:\/\/www.cancer.org\/acs\/groups\/content\/@editorial\/documents\/document\/acspc-047403.pdf"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.2557"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.1474"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4789"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2018.78.0619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T09:59:14Z","timestamp":1653818354000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2018.78.0619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,20]]},"references-count":34,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018,5,20]]}},"alternative-id":["10.1200\/JCO.2018.78.0619"],"URL":"https:\/\/doi.org\/10.1200\/jco.2018.78.0619","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,20]]},"assertion":[{"value":"2018-04-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}